CC
ALLO icon

Centiva Capital’s Allogene Therapeutics ALLO Stock Holding History

Centiva Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,101
Closed -$446K – 1252
2021
Q2 		$446K Buy
+17,101
New +$488K 0.01% 876

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Centiva Capital's ALLO Position: Q3 2021 in Review

Centiva Capital sold out of Allogene Therapeutics (ALLO) in Q3 2021, closing a stake of 17,101 shares — an estimated $446K sold.

Centiva Capital first reported a position in ALLO in Q2 2021 and held it in 1 quarter. The position peaked at $446K in Q2 2021. 169 funds tracked by Wall St. Rank hold ALLO as of Q3 2021.

  • Centiva Capital reported no remaining Allogene Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Centiva Capital sold 17,101 Allogene Therapeutics shares in Q3 2021, an estimated $446K.
  • Centiva Capital first reported a position in Allogene Therapeutics in Q2 2021 and held it in 1 quarter.
  • Centiva Capital's Allogene Therapeutics position peaked at $446K in Q2 2021.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2021.

Based on Centiva Capital's 13F filing for Q3 2021, filed 15 Nov 2021.